Ipragliflozin

Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter). It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ, Cay-13104), and nicotinamide (Cay-11127). It decreases plasma and hepatic IL-6, TNF-alpha, chemokine (C-C motif) ligand 2 (CCL2), and C-reactive protein (CRP) levels in the same model when administered at a dose of 3 mg/kg per day for 28 days.Formal Name: (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol. CAS Number: 761423-87-4. Synonyms: ASP1941. Molecular Formula: C21H21FO5S. Formula Weight: 404.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS (pH7.2) (1:7): 0.13 mg/ml. lambdamax: 231, 267 nm. SMILES: FC1=C(CC2=CC3=C(C=CC=C3)S2)C=C([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C=C1. InChi Code: InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1. InChi Key: AHFWIQIYAXSLBA-RQXATKFSSA-N.